A Phase Ib Age De-escalation and Dose Escalation Open Label Clinical Trial of the Safety, Immunogenicity and ex Vivo Efficacy of a Candidate Malaria Vaccine Pfs25-IMX313/Matrix-M Administered Intramuscularly in Healthy Adults and Young Children in Tanzania
Latest Information Update: 29 Jan 2025
At a glance
- Drugs Pfs25 Pfs230 malaria vaccine MVI (Primary)
- Indications Falciparum malaria
- Focus Adverse reactions
Most Recent Events
- 27 Jan 2025 Status changed from recruiting to discontinued.
- 21 Jun 2022 Planned End Date changed from 1 Jan 2023 to 1 Mar 2023.
- 21 Jun 2022 Planned primary completion date changed from 1 Jan 2023 to 1 Mar 2023.